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Background: Vasoactive intestinal polypeptide secreting tumors(VIPomas) are rare endocrine tumors of the
pancreas with an estimated incidence of 0.1 per million per year. The molecular mechanisms that mediate
development of VIPomas are poorly investigated and require definition.
Methods: A genome- and gene expression analysis of specimens of a primary pancreatic VIPoma with hepatic
metastases was performed. The primary tumor, the metastases, the corresponding healthy tissue of the liver,
and the pancreas were compared with each other using oligonucleotide microarrays and loss of heterozygosity
(LOH).
Results: The results revealed multiple LOH events and several differentially expressed genes. Our finding of LOH
and downregulation was conspicuous in the microarray analysis for the mismatch repair gene MSH2 in the
primary pancreatic VIPoma tumor, the hepatic metastasis but not in the corresponding healthy tissue. Further a
strong overexpression of the chemokine CXCR4 was detected in the hepatic metastases compared to its
pancreatic primary. With a review of the literature we describe the molecular insights of metastatic
development in VIPoma.
Conclusion: In VIPoma, defects in the mismatch repair system especially in MSH2 may contribute to
carcinogenesis, and increased CXCR4 may be associated with liver metastasis.
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Vasoactive intestinal polypeptide secreting tumor (VIPoma)
is a rare tumor associated with watery diarrhea, hypokal-
emia, and achlorhydria (WDHA) [1]. The estimated inci-
dence is approximately 0.1 per million per year [2].
VIPomas are mostly located in the pancreas, although they
have been already detected in the bronchial system, colon,
liver, adrenal gland, and sympathetic ganglia [3,4]. The
major causes of death concerning VIPomas are dehydration
and renal failure [5]. Clinical symptoms lead to the diagno-
sis. When symptoms present several patients already have
metastasis. The only curative approach is surgical resection
[6]. Until now the molecular mechanisms that mediate* Correspondence: derek.zieker@med.uni-tuebingen.de
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reproduction in any medium, provided the ordevelopment of metastases of VIPomas require definition
and were not investigated yet. Thus, we present this rare
entity by investigating a genome- and gene expression ana-




A 69-year-old man was referred from an outside hospital to
our department with masses in the liver and therapy-
resistent watery diarrhea. Since 1996 he had suffered from
protracted watery diarrhea. At that time the patient
received oral rehydration solutions and electrolyte supple-
mentation without regression of the symptoms. In Septem-
ber 1999 ultrasonography was performed and several
hepatic masses were detected. Subsequent biopsy of the
hepatic masses revealed the diagnosis of metastases due to
a malignant VIPoma without evidence of the location of
the primary. For further conservative treatment the patientLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 PET-CT with MBq 68-Gallium-DOTATOC showing
enhancement of multiple lesions in the right lobe of the liver
(upper image) and a slight enhancement in the caudal
pancreas (lower image).
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Thus, the patient was administered Rituximab and Roferon
additionally, so the progress of the symptoms was impeded.
During the course of treatment, minor relapses were com-
pensated using Capecitabine and Cetuximab as additional
medication. Regarding side effects of therapy,the patient
developed enormous acne. In December 2005 the patient
stopped responding to the performed conservative treat-
ment and suffered from massive watery diarrhea (5 to 10 L/
day), hypokalemia, achlorhydria, anemia, and severe meta-
bolic acidosis with consecutive acute renal failure and re-
quiring dialysis. Finally the patient was referred from an
outside hospital and was admitted to our hospital and de-
partment in February 2006. At admission computed tom-
ography (CT) and magnetic resonance imaging (MRI) were
performed. In the liver a 4.7 × 3.3 cm mass in segment VII,
a 6.6 cm mass in diameter in segment V/VI, and two
lesions with 2 cm and 1.7 cm in diameter in segment V
were detected. The findings showed an increase in size
compared to a previous CT scan performed in July 2005.
Since CT and MRI were not able to reveal the location of
the primary a PET-CT with MBq 68-Gallium-DOTATOC
was conducted. Enhancement of multiple lesions in the
right lobe of the liver and a slight enhancement in the cau-
dal pancreas without morphological circumscribable pri-
mary tumor were observed (see Figure 1). No infiltration of
lymph nodes or other organs was detected. Due to the cen-
sorious condition of the patient, at first a tumor-debulking
to decrease the amount of VIP causing the symptoms was
suggested. Plasma levels of VIP were between 450 and 650
pmol. Accordingly a hemihepatectomy was conducted in
March 2006 whereas the surgeon was able to palpate a le-
sion in the caudal pancreas intraoperatively. Based on the
severe condition of the patient, a simultaneous hemihepa-
tectomy and pancreasectomy was not able to be performed
at that time without putting patient’s life at risk. A liver
weighing 912 g and measuring 18.5 × 17.7 × 8.4 cm was
resected. Pathologic examination and immunohistochemis-
try revealed metastases due to a malignant VIPoma and ex-
pression of Chromogranin-A and Synaptophysin. In time
the condition of the patient stabilized. The symptoms
improved and the plasma VIP decreased (18 pmol). After a
reasonable recovery the patient underwent caudal pancrea-
sectomy and splenectomy in January 2007 with successful
resection of the primary tumor in sano. A pancreas speci-
men measuring 9 × 5 × 3 cm was resected. Pathologic
examination and immunohistochemistry revealed a pancre-
atic neuroendocrine tumor confirming a malignant VIPoma
with expression of Chromogranin-A and Synaptophysin.
The postoperative course was uneventful and the patient
did not show any further symptomatic. The follow-up
examinations with CT and MRIdid not reveal any recur-
rence or clinical symptoms, and VIP plasma levels were
low (2 pmol).Patients and tissue specimens
Histological proven tissue samples (primary pancreatic
VIPoma with hepatic metastases and corresponding
healthy tissue of the liver and the pancreas) of this pa-
tient were investigated. All tumor specimens were col-
lected by the Department of General, Visceral and
Transplant Surgery, University of Tübingen, Germany.
Specimens were snap frozen in liquid nitrogen and
stored at −80°C until use. Each tumor sample was cryo-
sected, stained with hematoxylin and eosin, classified by
two experience pathologists, and re-evaluated by an
experienced surgical pathologist. To ensure a tumor con-
tent >80%, microdissection was performed regarding
cancer specimens. The patients provided signed informed
consent. The study was approved by the local Ethics
Committee.RNA isolation
RNA was extracted using the NucleoSpin RNA II Kit
(Macherey-Nagel, Dueren, Germany). The RNA quality
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Bioanalyzer (Agilent Technologies, Palo Alto, CA,
USA) and the NanoDrop ND-1000 spectrophotometer
(NanoDrop Technologies, Wilmington, DE, USA).Microarray data generation and statistical analysis
Material and Methods concerning production and ana-
lysis of our oligonucleotide microarrays have been
described already by Zieker et al. [7,8]. In short:
Microarray analysis was performed using oligonucleo-
tide microarrays (65mer) produced at the Max Planck
Institute, Tübingen, Germany. The arrays contained oli-
gonucleotides for about 900 transcripts, and each oligo-
nucleotide was printed twice. Using 5 oligonucleotide
microarrays (including dye-swap) we compared the pri-
mary tumor, the metastases, the corresponding healthy
tissue of the liver, and the pancreas. Amplification of the
sample RNA was performed using Ambion’s Amino
AllylMessageAmp™ II aRNA Amplification Kit (Ambion
Inc., Austin, TX, USA). Dye-coupling reaction was per-
formed using Amersham CyDye Post-labelling Reactive
Dye Pack (GE Healthcare, Buckinghamshire, UK). After
an aRNA fragmentation using Ambion’s Fragmentation
Reagents (Ambion Inc., Austin, TX, USA), hybridization
was carried out at 48°C for 14 h. The slides were
scanned in a microarray scanner (Genetix Limited,
Hampshire, UK). The photomultiplier tube voltage was
set to 100% for both red and green channels. The two
resulting green and red images were overlaid using Ima-
Gene 5 (BioDiscovery, Inc., El Segundo, CA, USA). Raw
data collection was performed using ImaGene v.5.0. Fur-
ther statistical and bioinformatic analyses were per-
formed using the R language (www.r-project.org) and
the ‘limma’ (Linear Models for Microarray) package
from the Bioconductor project (http://www.bioconduc-
tor.org/). As a first step in signal extraction, for each
channel we used the mean of the pixel distribution for
the foreground signal and the median for the back-
ground of each spot as estimators of the raw signal
values. All spots were used, regardless of their flag sta-
tus. The data were normalized using loess normalization
on the normexp-background corrected expression values,
followed by a dye-swap normalization and in-between-
array quantile normalization. Both the loess and quantile
normalization methods were used as provided in the
limma package. On the basis of the M values computed,
differentially expressed genes were detected by applying
the Welch one-sample t-test as implemented in R.Microsatellite analysis
DNA was extracted from both tissue and patients’ blood
using the Gentra-DNA-extraction kit (Biozym) accord-
ing to the manufacturer’s instructions. The followingDNA samples derived from patients’ material were used
for microsatellite analysis:
M32: primary tumor
M32I: liver metastasis 1
M32II: liver metastasis 2
M32N: normal liver tissue
Data derived from these samples were compared to
results derived from blood DNA.LOH analysis
Microsatellite analysis was performed applying an
extended marker panel for endocrine tumors which was
previously established in our department [9]. In brief,
markers BAT25, BAT26, D2S123, and D17S250 were
amplified in a multiplex PCR (multiplex 1) using the
QIAGEN Multiplex PCR Master Mix (Qiagen) under
following conditions: final concentration of each forward
primer (dye labeled) was 0.2 μM, of each reverse primer
1 μM, DNA concentration was 100 ng. Asymmetric PCR
was used to reduce the ratio between primer signal and
amplicon signal thereby improving the fluorescence de-
tection threshold. Thermal cycling conditions were 94°C
for 5 min (94°C for 30 s, 54°C for 90 s, 72°C for 60 s), 30
cycles, 60°C for 5 min. PCR products were purified using
the QIAquick PCR purification kit (QIAGEN).
Microsatellite markers D2S443, D16S752, D21S1436
(multiplex 2) and D1S104, D3S1284 (multiplex 3) were
amplified in two multiplex PCR reactions under follow-
ing conditions: 200 ng DNA, 1 × PCR buffer, 0.08 mM
dNTPs each, 2 mM MgCl2, 1 U Taq, 0.8 μM primer
each, ad 50 μL H2O; 94°C for 2 min (94°C for 40 s, 53°C
(multiplex 2), and 61°C (multiplex 3) for 40 s, respect-
ively, 72°C for 1.30 min), 40 cycles, 72°C for 2 min. PCR
products derived from the same patients sample were
combined and purified using the PCR-purification kit
(Qiagen). LOH analysis was performed on an automated
capillary sequencer CEQ 8000 (Beckman Coulter) and
evaluated with the CEQ 8000 Fragment analysis software
(Beckman Coulter).LOHscoring
The tumor was considered to be positive for LOH if the
allele peak ratio was ≤0.7, in analogy with allelic signal
reduction of at least 30% [10]. Homozygous peaks were
classified as not informative and were not evaluated in
LOH statistics.Literature review
A Medline search was conducted for the term ‘VIPo-
ma’to December 2011. A total of 489 publications were
retrieved. All English written publications reporting on
oncogenesis were included. Articles dealing with clinical
Table 1 Comparison of gene up- and downregulation of the primary pancreatic tumor against its corresponding
healthy pancreatic tissue (>log2)
Geneproduct upregulated Log2ratio Geneproduct downregulated Log2ratio
Homo sapiens SMAD family member 5 (SMAD5) 2.60 Homo sapiens catenin (CTNNAL1) −2.01
Homo sapiens neural cell adhesion molecule 2 (NCAM2) 2.56 Homo sapiens adhesion regulating molecule 1 (ADRM1) −2.04
Homo sapiens cadherin-like 26 (CDH26) 2.46 Homo sapiens histonedeacetylase 2 (HDAC2) −2.29
Homo sapiens S100 calcium binding protein A9 (S100A9) 2.32 Homo sapiens cyclin L2 (CCNL2) −2.34
Homo sapiens mediator of DNA damage checkpoint 1
(MDC1)
2.25 Homo sapiens MSH2 (MSH2) −2.63
Homo sapiens adhesion molecule, (AMICA1) 2.24 Homo sapiens SMAD family member 6 (SMAD6) −2.71
Homo sapiens guaninenucleotide binding protein (G
protein)
−2.72
Homo sapiens cyclin-dependent kinase 5, (CDK5R2) −3.02
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comes were excluded.Results
Microarray analysis
Gene expression analysis was performed using a custom-
designed oligo microarray. We found a number of genes
that were up- or downregulated comparing the primary
tumor, the metastases, the corresponding healthy tissue
of the liver, and the pancreas.
Concerning the expression ratio we found 36 genes to
be differentially expressed (>log2). Eighteen genes upre-
gulated and 18 genes were downregulated. Comparing
the primary pancreatic tumor against its corresponding
healthy tissue six genes were upregulated and eight
genes were downregulated (>log2) (See Table 1). Five
genes were upregulated and five genes were downregu-
lated comparing the primary pancreatic tumor with the
hepatic metastases (>log2) (see Table 2). Regarding the
expression between the hepatic metastases and its corre-
sponding healthy liver tissue, seven genes were upregu-
lated and five genes were downregulated (>log2) (see
Table 3).
Regarding the gene expression of MSH2 and CXCR4
we were able to detect a downregulation (−2.80-fold) ofTable 2 Comparison of gene up- and downregulation of the p
(>log2)
Geneproduct upregulated Log2ratio G
Homo sapiens cyclin-dependent kinase 7 (CDK7) 4.52 H
Homo sapiens cadherin 4 (CDH4) 3.72 H
Homo sapiens cyclin D2 (CCND2) 3.06 H
Homo sapiens gapjunctionprotein, beta 5 (connexin 31.1)
(GJB5)
2.73 H
Homo sapiens lipase, hormone-sensitive 2.25 H
(CMSH2 in hepatic metastases and (−2.63-fold) of MSH2 in
the primary pancreatic tumor compared to both corre-
sponding healthy tissue. Comparing the hepatic metasta-
ses against the primary pancreatic tumor an upregulation
(10.41-fold) was detected.
LOH results
Ten microsatellite samples were used for MSI and LOH
detection (see Table 4).
All experiments were repeated at least twice. LOH events
were detected in several patient samples (see Figure 2).
Altogether, allele peak ratios for LOH calculation varied
between 0.60 and 0.12.
Sixty-three percent of markers analyzed showed LOH.
Nine percent of markers were not informative for LOH
calculation and 27% of markers showed microsatellite
stability. LOH was detected in primary tumor DNA as
well as in liver metastasis. Interestingly, two markers
(D5S326 and D21S1436) revealed LOH in normal liver
tissue. All tumor DNAs analyzed showed LOH for mar-
ker D2S123 which is located close to the MSH2.
Discussion
VIP-producing tumors arise from pancreatic islet cells
and are mostly located in the pancreatic body or tail [4].rimary pancreatic tumor against the hepatic metastases
eneproduct downregulated Log2ratio
omo sapiens acyl-CoA synthetase, (ACSM1) −2.17
omo sapiens cadherin 20, type 2 (CDH20) −2.27
omo sapiens HUS1 checkpoint (HUS1B) −2.67
omo sapiens chemokine (C-X-C motif) receptor 4 (CXCR4) −3.37
omo sapiens caudal type homeobox ranscription factor 2
DX2)
−3.39
Table 3 Comparison of gene up- and downregulation of the hepatic metastases and its corresponding healthy liver
tissue (>log2)
Geneproduct upregulated Log2ratio Geneproduct downregulated Log2ratio
Homo sapiens neuronal cell adhesion molecule (NRCAM) 2.76 Homo sapiens guanine nucleotide binding protein-like 2
(GNL2)
−2.23
Homo sapiens GNAS complex locus (GNAS) 2.58 Homo sapiens alanine-glyoxylate aminotransferase homolog
(TLH6)
−2.38
Homo sapiens cell division cycle and apoptosis regulator 1
(CCAR1)
2.51 Homo sapiens MSH2 (MSH2) −2.80
Homo sapiens cyclin-dependent kinase inhibitor (CDKN1C) 2.48 Homo sapiens gap junction protein, beta 1 (GJB1) −2.87
Homo sapiens cytochrome c oxidase subunit VIIa polypeptide
2 (liver)
2.29 Homo sapiens caspase 1 (CASP1) −3.21
Homo sapiens mucin and cadherin-like (MUCDHL) 2.09
Homo sapiens cyclin D1 (CCND1) 2.04
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sis [11]. The clinical symptoms accompanying the tumor
are watery diarrhea, hypokalemia, and metabolic acid-
osis. At the time of presentation, over 70% of patients
had hepatic metastases [12]. Hence, understanding the
molecular mechanisms of tumor progression is of para-
mount importance. Our results revealed defects in the
mismatch repair system especially in MSH2. MSH2
showed significantly lower expression in the primary
pancreatic tumor and its liver metastases than in healthy
pancreatic tissue. Further an overexpression of CXCR4
in the hepatic metastasis compared with the primary
was detected.
Reviewing the literature,eight cohorts including 161
patients and 133 case reports exist on VIPoma. Only six
publications deal with the molecular mechanisms of




D1S104 1q21-23 LOH 0.2
D2S443 2p13 LOH 0.19
BAT26 2p16 MSS >0.
D2S123 2p16 LOH 0.21
D3S1284 3p12 LOH 0.19
BAT25 4q12 MSS >0.
D5S326 5q22.2 LOH 0.2
D16S752 16q22 LOH 0.12
D17S250 17q11.2-12 MSS >0.
D21S1436 21q21 LOH 0.6
AP ratio, Allele peak ratio; LOH, Loss of heterozygosity; MSS, Microsatellite stable.reporting no more than two cases in each publication
[13-18]. The remaining publication reports on the clin-
ical presentation, diagnostics, and therapeutic options.
Amongst others, mutations in the tumor suppression
genes DPC4 [15], AIM1 (‘absent in melanoma1’) and
PTPRK (receptor type protein-tyrosine phophastase
kappa) [14] are shown in metastatic VIPomas while
mutations of the proto oncogene BRAF known to play
an important role in thyroid cancer and melanoma were
not found [15,18]. A series of 35 neuroendocrine tumors
of the pancreas showed that defects in DNA mismatch
repair are rather rare with the limitation, that no
VIPoma case was included [19].
The DNA mismatch repair system (MMR) corrects
base mismatches after DNA replication, avoids recombin-
ation between non-identical DNA sequences, and induces
apoptotic and checkpoint responses after DNA damagen in pancreatic tumor tissue, liver metastasis tissue, and
Liver metastasis Normal liver
ratio AP ratio AP ratio
LOH 0.49 MSS >0.7
LOH 0.42 MSS >0.7
7 MSS >0.7 MSS >0.7
LOH 0.45 MSS >0.7
LOH 0.47 MSS >0.7
7 MSS >0.7 MSS >0.7
LOH 0.31 LOH 0.32
LOH 0.39 MSS >0.7
7 MSS >0.7 MSS >0.7
LOH 0.4 LOH 0.59
A B C
Pancreas tumor        
Liver metastasis 1       
Liver metastasis 2      
Normal Liver              
    Normal Pancreas   
Figure 2 Loss of heterocygosity (arrow) for the markes D2S443 (A), D3S1284 (B), and D21S1436 (C) in pancreas tumor tissue, liver
metastases tissue (1&2), normal liver and normal pancreas tissue.
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assumed to a great extent to be involved in carcinogenesis
[21]. So far hundreds of different predisposing mutations
are known, mainly affecting the MMR genes, MLH1,
MSH2, and MSH6. Predisposed individuals exhibit a defi-
cient copy of a MMR gene in each cell. Deficient MMR,
characteristic in the colon can lead to proceeding accu-
mulation of mutations and cancer, such as hereditary
non-polyposis colon cancer (HNPCC), is known to be a
syndrome of insufficient DNA mismatch repair genes
[21]. Instability at short tandem repeat sequences, micro-
satellites, is a representative manifestation of MMR defi-
ciency and beside HNPCC also occurs in other tumors
[20]. In particular deficient MSH2 is associated with an
increased risk of cancer [22].
Chemokines and their respective receptors have been
identified as contributing metastatic factors in numerous
cancers [23,24]. The common human chemokine system
includes about 50 ligands and 20 G protein-coupled
receptors which control migration and activation of leu-
kocytes and influences angiogenesis and tumor growth
[25]. Recent discoveries assume that tumor cells them-
selves are able to secrete chemokines [25-27]. Therefore
disseminated tumor cells that express members of the
CXCR family and invade the circulation may be
attracted and arrested by their corresponding ligand.
Hence these cells gain the ability to infiltrate in distinct
organs. CXCR4 is assumed to be involved in metastasisof non-small-cell lung, breast, pancreatic, prostate, gas-
tric cancer, and peritoneal carcinomatosis [27-32].
Deschamps et al. found CXCR4 to be associated with
the malignant metastatic progression of neuroendocrine
tumors of the ileum correlated with a lower survival
[33]. So far, mutation of MSH2 and CXCR4 and its in-
volvement in tumor growth and metastasis development
have not been reported in VIPoma.Conclusions
Altogether, the altered expression of MSH2 and CXCR4
in a metastatic VIPoma might reflect higher tumor
aggressivity with the potential development of distant
metastases. Owing to the rarity of this disease, we be-
lieve these results will provide a valuable resource for fu-
ture work on this serious condition with the potential of
diagnostic applications.Competing interests
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